- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
- Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
More ▼
Key statistics
On Tuesday, Eledon Pharmaceuticals Inc (ELDN:NAQ) closed at 2.87, -14.30% below its 52-week high of 3.35, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.81 |
---|---|
High | 2.95 |
Low | 2.70 |
Bid | 2.72 |
Offer | 2.92 |
Previous close | 2.80 |
Average volume | 168.61k |
---|---|
Shares outstanding | 38.51m |
Free float | 37.16m |
P/E (TTM) | -- |
Market cap | 105.89m USD |
EPS (TTM) | -1.41 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 21:00 BST.
More ▼